Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Inclusion Criteria:

• Subjects with a diagnosis of FDG-avid relapsed or refractory classical HL OR selectsubtypes of FDG-avid CD30-positive relapsed or refractory PTCL

• For subjects with R/R PTCL a pre-enrollment tumor biopsy positive for CD30 locallyassessed by Ber-H2 targeted immunohistochemistry at ≥1% is mandatory (PTCL subtypes:PTCL-NOS, Angioimmunoblastic T-cell lymphoma, ALCL, anaplastic lymphoma kinase (ALK)-positive, ALCL, ALK-negative)

• Subjects with R/R classical HL must have received at least two lines of therapyincluding one prior line of combination chemotherapy. Prior therapy must also haveincluded brentuximab vedotin and a PD1 check point inhibitor.

• Subjects with R/R PTCL must have received at least one prior line of combinationchemotherapy. Subjects with ALCL subtype of PTCL must have received or beenintolerant to brentuximab vedotin.

• Subjects with R/R classical HL AND R/R PTCL: Prior ASCT is permitted if completed atleast 3 months prior to the first dose of study treatment. Prior allogeneic stemcell transplantation will be permitted if completed at least 1 year from studyenrollment and there are no signs or symptoms of GVHD. Prior CAR-T therapy ispermitted if last CAR-T dose completed at least 6 months prior to the first dose ofstudy treatment.

• Ability to understand and sign the ICF

Exclusion Criteria:

• Active central nervous system (CNS) involvement (untreated or uncontrolledparenchymal brain metastasis or positive cytology of cerebrospinal fluid)

• Previous treatment with AFM13 or CBNK cells

• History of a solid organ allograft, or an inflammatory or autoimmune disease likelyto be exacerbated by IL-2 (including subjects requiring systemic treatment withinthe past 3 months or a documented history of clinically severe autoimmune diseasethat may require systemic steroids or immunosuppressive agents

• Treatment with any therapeutic mAb or immunosuppressive medications

• Known active Hepatitis B or C defined per protocol

• Active HIV Infection

• History of any other systemic malignancy, unless previously treated with curativeintent and the subject has been disease free for 2 years or longer

• Active acute or chronic graft vs. host disease (GVHD) or GVHD requiringimmunosuppressive treatment, clinically significant central nervous system (CNS)dysfunction